BIOFILM

Antibiofilmogram Test

BIOFILM est accrédité par Lyonbiopôle

Identity card

Global budget: 4310 k€

Public funding: 1285 k€

Public funders: Conseil général du Puy de Dôme, FEDER Auvergne, Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Région Auvergne

Call for projects: FUI (FUI AAP15)

Year start: 2013

Completed project (2017-12)


Accredited by the French competitiveness cluster Lyonbiopôle

Co-accredited by the French competitiveness cluster Alsace BioValley

More information: http://www.antibiofilmogramme.fr


Strategic business area: In vitro Diagnostic

Application fields: Infectious diseases

Technological approaches / Keywords: Biologics, Diagnosis

Stage of development at the beginning of the project: Discovery

Abstract

The project is based on the assumption that the development of an in vitro biofilm in the presence of antibiotics is correlated with a decrease in the effectiveness of the antibiotic treatment.  This project aims to: •Demonstrate the clinical value of an early detection of the biofilm in response to antibiotic treatment. •Allow a rapid adaptation of the empirical treatment administered with a fast result at J+1. •Choose the best antibiotic treatment for wounds care and chronic infections  The Antibiofilmogramme® will be a new tool to fight against multidrug-resistant infections. 


Objectives

The project aims to develop a brand new antibiogram test, named Antibiofilmogramme®, that will take into account the "biofilm” behaviour and its medical value to prevent therapeutic failures. The BIOFILM project offers the possibility to the French consortium and in particular to BioFilm Control to compete at the highest level. The recognized experience of the consortium partners on their core activity combined with their critical size is ideal to launch the revolutionary test on the international market and obtain a scientific, industrial and economic success. 


Innovative assets
Highlights
Perspectives

Innovative assets

The BIOFILM project will provide several major innovations: • Development of a new automated antibiogram test (a rapid test able to detect virulent strains within 6 hours rather than 10h to 16 hours (and more) actually) • Provide guidelines and recommendations regarding the interpretation of in vitro antibiogram test, in the future the biofilm behavior of germs may be taken into account when an antibiotic treatment is prescribed • The R&D studies with our clinical partners will provide an R&D synergy to discover new ways of treating infections multi-resistant or not.  

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte